Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

Share Price Information for Iconic Labs (ICON)

Share Price is delayed by 15 minutes
Get Live Data
1.70    0.10 (6.25%)
Bid:
1.55
Ask:
1.85
Spread: 0.30 (19.355%)
Market Cap: £264.88k
ICON Live PriceLast checked at - London Stock Exchange

Intraday Iconic Labs Share Chart

Update

8 Mar 2019 16:47

RNS Number : 3695S
WideCells Group PLC
08 March 2019
 

 

8 March 2019

 

 

WideCells Group PLC ("WideCells" or the "Company")

Update

WideCells Group PLC, announces that, following the issuance of the Prospectus on 22 February 2019, and pursuant to the financing agreement entered into by the Company and the European High Growth Opportunities Securitization Fund (the "Investor") (see RNS dated 6 November 2018), pursuant to which the Company issued bonds ("Convertible Bonds") convertible into ordinary shares of £0.0025 each in the Company ("Ordinary Shares") to the Investor, the Company has today received a further notice of exercise from the Investor in respect of the exercise by the Investor of its conversion rights under the Convertible Bonds for the principal amount of £80,000, together with a penalty payment of £120,000, resulting in the issue to the Investor of 80,000,000 new Ordinary Shares ("Conversion Shares").

The Company has agreed, subject only to Admission (as defined below), to issue the Conversion Shares and accordingly application will be made for the Conversion Shares to be listed on the Standard segment of the Official List of the UK Listing Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc ("Admission").

Admission is expected to take place on 12 March 2019. The Conversion Shares will rank pari passu in all respects with all existing Ordinary Shares.

Following Admission of the Conversion Shares, the Company's enlarged issued share capital will compromise 291,352,698 Ordinary Shares with voting rights. The Company does not hold any shares in treasury. The figure of 291,352,698 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

Further to the announcement made by the Company on 6 March 2019, concerning the drawdown notice issued by the Company and the issue of Convertible Bonds, the Company wishes to correct the announcement as follows:

The Company issued a further drawdown notice under the financing agreement to the Investor for the aggregate sum of up to £1,465,000, for which the Company shall issue Convertible Bonds to the Investor on the following basis:

I. £1,000,000 to be subscribed for and paid to the Company immediately;

II. £265,000 to be subscribed for and paid to the Company on 6 June 2019; and

III. thereafter, following the 6 June 2019, one further tranche of £200,000 to be subscribed for and paid to the Company on the date which is 40 days after the 6 June 2019 (or the next business day). 

 

Market Abuse Regulation (MAR) Disclosure - certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

ENDS

For further information, please visit the Company's website www.widecellsgroup.com or contact:

 

 

 

 

Shard Capital Partners LLP

Broker - Damon Heath & Erik Woolgar

Tel: +44 (0) 20 7186 9950

St Brides Partners Limited

PR - Melissa Hancock & Isabel de Salis

Tel: +44 (0) 20 7236 1177

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCQVLFBKXFZBBL
Date   Source Headline
21st Feb 20234:40 pmRNSSecond Price Monitoring Extn
21st Feb 20234:35 pmRNSPrice Monitoring Extension
21st Feb 20232:05 pmRNSSecond Price Monitoring Extn
21st Feb 20232:00 pmRNSPrice Monitoring Extension
20th Feb 20234:35 pmRNSPrice Monitoring Extension
20th Feb 20237:49 amRNSDirector Appointment
16th Feb 20239:05 amRNSSecond Price Monitoring Extn
16th Feb 20239:00 amRNSPrice Monitoring Extension
15th Feb 20233:00 pmRNSTR-1 notification
15th Feb 20233:00 pmRNSTR-1 notification
15th Feb 20233:00 pmRNSTR-1 notification
15th Feb 20233:00 pmRNSTR-1 notification
15th Feb 20233:00 pmRNSTR1 notification
15th Feb 20233:00 pmRNSTR1 notification
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 20239:05 amRNSSecond Price Monitoring Extn
10th Feb 20239:00 amRNSPrice Monitoring Extension
10th Feb 20237:00 amRNSSubscription of Convertible Notes
9th Feb 20232:00 pmRNSPrice Monitoring Extension
9th Feb 20231:04 pmRNSConversion of Securities
8th Feb 20234:40 pmRNSSecond Price Monitoring Extn
8th Feb 20234:35 pmRNSPrice Monitoring Extension
8th Feb 20232:05 pmRNSSecond Price Monitoring Extn
8th Feb 20232:00 pmRNSPrice Monitoring Extension
6th Feb 20237:18 amRNSConversion of Notes
2nd Feb 20237:55 amRNSRestructuring Update
31st Jan 20232:05 pmRNSSecond Price Monitoring Extn
31st Jan 20232:00 pmRNSPrice Monitoring Extension
31st Jan 202311:05 amRNSSecond Price Monitoring Extn
31st Jan 202311:00 amRNSPrice Monitoring Extension
31st Jan 20238:52 amRNSTotal Voting Rights
30th Jan 20234:40 pmRNSSecond Price Monitoring Extn
30th Jan 20234:35 pmRNSPrice Monitoring Extension
30th Jan 20238:04 amRNSConversion of Securities & Resignation of Director
27th Jan 202311:05 amRNSSecond Price Monitoring Extn
27th Jan 202311:00 amRNSPrice Monitoring Extension
25th Jan 202312:08 pmRNSRestoration of Trading
25th Jan 20239:00 amRNSPrice Monitoring Extension
24th Jan 20234:40 pmRNSSecond Price Monitoring Extn
24th Jan 20234:35 pmRNSPrice Monitoring Extension
24th Jan 202312:00 pmRNSRestoration - Iconic Labs Plc
16th Jan 20235:24 pmRNSUpdate Regarding Sting Industries Acquisition
16th Jan 20237:00 amRNSIPEM
6th Jan 20238:10 amRNSCorporate Update
3rd Jan 20234:48 pmRNSAnnual Financial Report 2022
29th Dec 20223:58 pmRNSFinal Results 2021
22nd Dec 20229:02 amRNSFinancing Facility
16th Dec 20227:00 amRNSRegulatory Approval
14th Dec 20226:31 pmRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.